tradingkey.logo
tradingkey.logo
Search

Standard BioTools Inc

LAB
Add to Watchlist
0.913USD
+0.046+5.32%
Close 07/02, 13:00ETQuotes delayed by 15 min
356.16MMarket Cap
4.57P/E TTM

TradingKey Stock Score of Standard BioTools Inc

Currency: USD Updated: 2026-07-02

Key Insights

Standard BioTools Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 86 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.55.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Standard BioTools Inc's Score

Industry at a Glance

Industry Ranking
86 / 204
Overall Ranking
199 / 4565
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Standard BioTools Inc Highlights

StrengthsRisks
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 85.33M.
Overvalued
The company’s latest PE is 4.57, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 317.36M shares, increasing 0.24% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 50.85M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.91.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
1.550
Target Price
+78.82%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Standard BioTools Inc?

The TradingKey Stock Score provides a comprehensive assessment of Standard BioTools Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Standard BioTools Inc’s performance and outlook.

How do we generate the financial health score of Standard BioTools Inc?

To generate the financial health score of Standard BioTools Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Standard BioTools Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Standard BioTools Inc.

How do we generate the company valuation score of Standard BioTools Inc?

To generate the company valuation score of Standard BioTools Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Standard BioTools Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Standard BioTools Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Standard BioTools Inc.

How do we generate the earnings forecast score of Standard BioTools Inc?

To calculate the earnings forecast score of Standard BioTools Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Standard BioTools Inc’s future.

How do we generate the price momentum score of Standard BioTools Inc?

When generating the price momentum score for Standard BioTools Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Standard BioTools Inc’s prices. A higher score indicates a more stable short-term price trend for Standard BioTools Inc.

How do we generate the institutional confidence score of Standard BioTools Inc?

To generate the institutional confidence score of Standard BioTools Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Standard BioTools Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Standard BioTools Inc.

How do we generate the risk management score of Standard BioTools Inc?

To assess the risk management score of Standard BioTools Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Standard BioTools Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Standard BioTools Inc.